Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 1
Results: 22
Correction to: Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 223, doi. 10.1007/s00262-022-03247-9
- By:
- Publication type:
- Article
Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 211, doi. 10.1007/s00262-022-03246-w
- By:
- Publication type:
- Article
High salt diet does not impact the development of acute myeloid leukemia in mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 265, doi. 10.1007/s00262-022-03244-y
- By:
- Publication type:
- Article
Correction to: Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 235, doi. 10.1007/s00262-022-03242-0
- By:
- Publication type:
- Article
The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 169, doi. 10.1007/s00262-022-03240-2
- By:
- Publication type:
- Article
Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 151, doi. 10.1007/s00262-022-03239-9
- By:
- Publication type:
- Article
Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 125, doi. 10.1007/s00262-022-03236-y
- By:
- Publication type:
- Article
Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 101, doi. 10.1007/s00262-022-03235-z
- By:
- Publication type:
- Article
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 137, doi. 10.1007/s00262-022-03234-0
- By:
- Publication type:
- Article
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 91, doi. 10.1007/s00262-022-03232-2
- By:
- Publication type:
- Article
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 257, doi. 10.1007/s00262-022-03231-3
- By:
- Publication type:
- Article
Hematologic malignancies following immune checkpoint inhibition for solid tumors.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
The impact of body mass index on overall survival in patients with cancer receiving immunotherapy: a dose-response meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 275, doi. 10.1007/s00262-022-03229-x
- By:
- Publication type:
- Article
Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 55, doi. 10.1007/s00262-022-03228-y
- By:
- Publication type:
- Article
TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 193, doi. 10.1007/s00262-022-03227-z
- By:
- Publication type:
- Article
Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 73, doi. 10.1007/s00262-022-03226-0
- By:
- Publication type:
- Article
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 183, doi. 10.1007/s00262-022-03225-1
- By:
- Publication type:
- Article
Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 23, doi. 10.1007/s00262-022-03221-5
- By:
- Publication type:
- Article
Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 1, doi. 10.1007/s00262-022-03215-3
- By:
- Publication type:
- Article
An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 1, p. 39, doi. 10.1007/s00262-022-03214-4
- By:
- Publication type:
- Article